Vioxx's Heart Risk Lingered Long After Use Ended

"There was always a signal that it [the risk] was worse for Vioxx that other cox-2 inhibitors. Whether or not other drugs like Celebrex shared that isn't known. That has not been demonstrated in studies of Celebrex. But you have to be suspicious, particularly since high doses of Celebrex have heart attack and stroke risk. But there's never been a study to show that it's a long-lasting liability," he said.

In response to the Lancet study, Vioxx manufacturer Merck issued the following statement: "Merck believes that this post-hoc analysis using limited data from a prematurelyterminated study needs to be interpreted very cautiously and in the context of the rest of thedata from the extensive clinical development program for Vioxx."

More information

For more about pain relievers, visit the U.S. National Library of Medicine.